F
Federico Rojo
Researcher at Hebron University
Publications - 193
Citations - 11809
Federico Rojo is an academic researcher from Hebron University. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 35, co-authored 144 publications receiving 11102 citations. Previous affiliations of Federico Rojo include Autonomous University of Barcelona.
Papers
More filters
Journal ArticleDOI
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
Arkaitz Carracedo,Li Ma,Li Ma,Li Ma,Julie Teruya-Feldstein,Federico Rojo,Leonardo Salmena,Leonardo Salmena,Andrea Alimonti,Andrea Alimonti,Ainara Egia,Ainara Egia,Atsuo T. Sasaki,George Thomas,Sara C. Kozma,Antonella Papa,Antonella Papa,Caterina Nardella,Caterina Nardella,Lewis C. Cantley,José Baselga,Pier Paolo Pandolfi,Pier Paolo Pandolfi +22 more
TL;DR: MAPK activation as a consequence of mTORC1 inhibition is identified and the potential of a combined therapeutic approach with m TORC1 and MAPK inhibitors, currently employed as single agents in the clinic, for the treatment of human cancers is underscore.
Journal ArticleDOI
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
José Baselga,D. Rischin,M. Ranson,H. Calvert,E. Raymond,D G Kieback,Stan B. Kaye,Luca Gianni,Adrian L. Harris,Thomas Björk,Steven D. Averbuch,A Feyereislova,H. Swaisland,Federico Rojo,Joan Albanell +14 more
TL;DR: ZD1839 treatment resulted in clinically meaningful disease stabilization across a range of tumor types and doses, and was generally well tolerated, with manageable and reversible AEs at doses up to 600mg/d and dose-limiting toxicity observed at 1,000 mg/d.
Journal Article
Trastuzumab (Herceptin), a Humanized Anti-HER2 Receptor Monoclonal Antibody, Inhibits Basal and Activated HER2 Ectodomain Cleavage in Breast Cancer Cells
Miguel Angel Molina,Jordi Codony-Servat,Joan Albanell,Federico Rojo,Joaquín Arribas,José Baselga +5 more
TL;DR: It is proposed that the inhibition of HER2 cleavage and prevention of the production of an active truncated HER2 fragment represent a novel mechanism of action of trastuzumab.
Journal ArticleDOI
Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
Maurizio Scaltriti,Federico Rojo,Alberto Ocaña,Judit Anido,Marta Guzman,Javier Cortes,Serena Di Cosimo,Xavier Matias-Guiu,Santiago Ramón y Cajal,Joaquín Arribas,José Baselga +10 more
TL;DR: Breast tumors that express p95HER2 are resistant to trastuzumab and may require alternative or additional anti-HER2-targeting strategies, and women with HER2-overexpressing breast cancers that express this receptor should be responsive to these agents.
Journal ArticleDOI
PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.
Incheol Shin,F. Michael Yakes,Federico Rojo,Nah-Young Shin,Andrei V. Bakin,José Baselga,Carlos L. Arteaga +6 more
TL;DR: Data indicate that Akt may contribute to tumor-cell proliferation by phosphorylation and cytosolic retention of p27, thus relieving CDK2 from p27-induced inhibition.